Status:
COMPLETED
Primary UVB-311nm and Adalimumab in Psoriasis Patients
Lead Sponsor:
Medical University of Graz
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis. However, in a portion of cases adalimumab does not i...
Detailed Description
Patients with moderate to severe psoriasis who are scheduled to receive a standard treatment course of adalimumab (loading dose of 80 mg and thereafter 40 mg s.c. biweekly) are exposed to UVB-311nm ph...
Eligibility Criteria
Inclusion
- Psoriasis patients who are scheduled for treatment with adalimumab.
Exclusion
- Pregnancy or lactation
- History of skin cancer
- Presence of or history of malignant skin tumors
- Dysplastic melanocytic nevus syndrome
- Antinuclear antibodies (ds-DNA, Ro/SSA, La/SSB)
- Autoimmune disorders such as Lupus erythematosus or Dermatomyositis
- Photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosum, basal cell nevus syndrome, and others
- General poor health status
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00638261
Start Date
March 1 2008
End Date
August 1 2011
Last Update
March 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Graz, Department of Dermatology
Graz, Austria, A-8036